News about Global Pharma

Dizal's Sunvozertinib Receives FDA Priority Review for EGFR-Mutated NSCLC Treatment

Dizal's Sunvozertinib, an oral EGFR inhibitor for advanced NSCLC with EGFR exon20ins mutations, receives FDA priority review, marking a milestone in addressing unmet needs in cancer treatment.

Global Pharma | 07/01/2025 | By Manvi |  394

Sentynl Therapeutics' CUTX-101 for Menkes Disease Gets FDA Priority Review

Sentynl Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted for filing and priority review of Sentynl’s New Drug Application (NDA) for CUTX-101, the product candidate for the treatment of Menkes disease.

Global Pharma | 07/01/2025 | By Manvi |  522

Amylyx Pharmaceuticals Welcomes Dan Monahan as Chief Commercial Officer

Throughout his career, Monahan has remained deeply committed to launching therapies that address high unmet medical needs, bringing critical treatments to those who need them most.

Global Pharma | 07/01/2025 | By Aishwarya |  479

Zuellig Pharma Acquires Propan from ADP Pharma in Philippines

The acquisition of Propan marks Zuellig Pharma's continued expansion into consumer healthcare as it strategically innovates its offerings to meet Asia's evolving healthcare needs.

Global Pharma | 07/01/2025 | By Aishwarya |  1239

Asieris, CDC Sign Investigational Drug Supply Agreement for APL-1202 in Amoeba Infections Treatment

Asieris Pharmaceuticals announced the signing of an investigational drug supply agreement under the Expanded Access Investigational New Drug (IND) Program with the Centers for Disease Control and Prevention (CDC) in the United States.

Global Pharma | 06/01/2025 | By Manvi |  546

Park Systems Acquires Lyncee Tec to Expand Optical Metrology Portfolio

This acquisition by Park Systems strengthens their optical metrology business, following its 2022 acquisition of Accurion GmbH, the manufacturer of Imaging Spectroscopic Ellipsometers (ISE).

Global Pharma | 06/01/2025 | By Aishwarya |  513

China's NMPA Approves VYLOY for Advanced Gastric Cancer Treatment

Astellas Pharma Inc. announced that China’s National Medical Products Administration (NMPA) has approved VYLOY (zolbetuximab), the first monoclonal antibody targeting CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma, for use with chemotherapy as a first-line treatment in HER2-negative, advanced, or metastatic cases.

Global Pharma | 06/01/2025 | By Manvi |  438

JCR Pharmaceuticals and Modalis to Develop Novel Gene Therapy

The purpose of this joint agreement is to conduct pre-clinical studies for the development of a new gene therapy for the undisclosed CNS disease by applying J-Brain Cargo®, JCR’s proprietary technology.

Global Pharma | 06/01/2025 | By Aishwarya |  503

Upperton Announces Appointment of Lorna Patrick as Chief Operating Officer

Lorna has over 20 years of experience in drug development, optimising operational processes and change management across a variety of roles including manufacturing, analytical, project management, clinical operations, and regulatory affairs.

Global Pharma | 04/01/2025 | By Aishwarya |  502

Eton Pharmaceuticals Announces Acquisition of Galzin

Galzin is FDA-approved as a maintenance treatment of patients with Wilson Disease who have been initially treated with a chelating agent.

Global Pharma | 04/01/2025 | By Aishwarya |  339